We partnered with a major research center that was recruiting a rare subset of Parkinson’s Disease patients with specific reactions to a commonly prescribed therapy.
2 years into the recruitment phase of the trial, they had only enrolled 31 patients, 36% of their goal.
The sponsor was over budget and concerned that they would not be able to complete enrollment by their deadline.